A prenatal test is a test that enables the prospective mother to learn the genetic problems that may emerge in her baby before birth.
NIPT is a next-generation non-invasive prenatal test.
It detects fetal chromosomal aneuploids and microdeletions by scanning fetal DNA from the mother’s blood.
NIPT utilizes the new Targeted Enrichment Technology to enable the detection of the fetal fraction as well as the aneuploidy with unique accuracy.
Targeted regions, selected chromosomes, and chromosomal regions are captured, and Enriched Bioinformatic Technologies and analyzed proprietary genomic microdeletions are used for aneuploidy detection.
It can be performed from the 10th week of pregnancy.
It is also confirmed for single and twin pregnancies as well as for IVF pregnancies.
It is a single test for screening for aneuploidies, microdeletions, and point mutations (*).
It does not require any procedure other than phlebotomy from the mother. No special conditions (hunger, etc.) are needed for phlebotomy. The analysis concludes in 10 days.
Advantage of Early Detection
The fact that it is applicable from the 10th week of pregnancy provides an advantage to both the doctor and the family for the decisions to be made in the clinic in the following stages.
Safe Method, Reliable Results
Interventional (invasive) methods are recommended in other screening methods, but these methods carry low or infection risks. In addition to the limited reliability of routine screening tests, the false positivity or false negativity rate is also high. However, the false negativity rate is fairly low in the NIPT test. The accuracy of risks associated with advanced maternal age, which are also detected in invasive screening tests with NIPT, is determined.